Twenty-one ammonia-powered ships are scheduled for delivery by 2029, with most expected within nine months. Q3 results are ...
The change took effect immediately, leaving TORM with five board members. Boehringer joined in 2015 and served for 11 years, ...
On-mine cost guidance rose to $1,700-$1,900 per ounce sold; group capex fell to $94.3 million. Normalized production is ...
Leeds and Oxford are the initial sites. NHSBT collects immune cells and handles cell material as partners explore expansion to more locations in England.
The planned facility is envisioned to produce hundreds of fusion machines annually; TRIDEC will coordinate site evaluation, ...
The trial also reported complete symptom resolution at 11.95 hours, no safety signals, and regulatory applications under ...
Secured capacity totals about 273.5MW, or about 78% of a target of up to 350MW by Q1 2028; full campus delivery is targeted ...
CMS rated Clover’s HMO plan 4.5 stars; with 20 measures included, its PPO rating would be 4.5. Clover’s HEDIS score was 4.82 ...
The average price was $158.2702 per share; the company bought the shares through Goldman Sachs International on the London ...
Canadian clients will gain access to insurance placement, specialty risk consulting and portfolio analysis, helping investors assess acquisition and operating risks earlier.
In the 712-patient ATOMIC trial, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy, versus 76% with chemotherapy alone.
In ATOMIC, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy versus 76% with chemotherapy alone; Roche is pursuing European filings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results